| Current Price | $18.80 | Mkt Cap | $1.1B |
|---|---|---|---|
| Open | $18.32 | P/E Ratio | -9.47 |
| Prev. Close | $18.80 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $17.82 - $18.82 | Volume | 622,715 |
| 52-Wk Range | $16.49 - $38.20 | Avg. Daily Vol. | 393,121 |
| Current Price | $18.80 | Mkt Cap | $1.1B |
|---|---|---|---|
| Open | $18.32 | P/E Ratio | -9.47 |
| Prev. Close | $18.80 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $17.82 - $18.82 | Volume | 622,715 |
| 52-Wk Range | $16.49 - $38.20 | Avg. Daily Vol. | 393,121 |
The best Bull and Bear pitches based on recency and number of recommendations.
When I first added Xencor to my database nine months ago I liked the company's proprietary platform of genetically engineered antibodies optimized for better binding to effector cells via the Fc domain. It seemed like there was a lot of potential for… More
There are no pitches that meet the Top Bear criteria. Explain
If this upsets you, start recommending pitches below!
Read the most recent pitches from players about XNCR.
Recs
TMFTypeoh
(90.43)
Submitted: 4/3/2018 4:51:13 PM :
Start Price:
$28.41
NASDAQ:XNCR Score:
-112.67
How have I not green thumbed this stock already? Interesting drug development platform and partnerships galore. Cash heavy balance sheet and low burn rate. Lots to like here.
Recs
sullyz0r
(36.63)
Submitted: 2/1/2015 11:23:46 AM :
Start Price:
$15.15
NASDAQ:XNCR Score:
-105.47
Strange decline after great news. I expect an SEC filing that some big VC took the good news to get out--fine by me. Antibody therapeutics are already huge and are going to be enormous. Making the antibodies better (which is what this company does) is going to have huge implications, and all the big pharmas and their brothers will want to partner with XNCR.
Recs
line70day
(< 20)
Submitted: 7/11/2014 12:33:56 PM :
Start Price:
$9.71
NASDAQ:XNCR Score:
-38.77
XNCR First Q. Cash balance totaled $72.5 M compared to $78.0 M Dec. 31,2012 rev.for first Q. 2014 were s2.2 M compared to $ l.3 M same Qlast yr. NET LOSS FIRSTQ ENDING March 31, 2014 was $3.7M on a fully diluted per shares bases to a net loss of $4.6 Mon fullydiluted per share basis for same period in 1213 decresereflects increased revenue and lower expences in first Q. 2014 compared to Q 2013 decrease reflects outstanding asa result of their IPO inDec 2013
Find the members with the highest scoring picks in XNCR.
TrackCreditSuiss (< 20) Score: +199.00
The Score Leader is the player with the highest score across all their picks in XNCR.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| biotechf | 40.98 | 2/8/2016 |
|
5Y | $10.60 | +77.26% | +147.13% | +69.87 | 0 Comment | |
| Bigcaps19 | 37.13 | 9/30/2022 |
|
5Y | $25.53 | -26.40% | +26.89% | +53.29 | 0 Comment | |
| cthomasset | 68.18 | 12/9/2013 |
|
5Y | $7.89 | +138.15% | +152.99% | -14.84 | 0 Comment | |
| EvilEmpire | 25.96 | 5/21/2014 |
|
5Y | $8.25 | +127.87% | +144.07% | -16.20 | 0 Comment | |
|
TerryFool | < 20 | 2/14/2014 |
|
5Y | $8.89 | +111.36% | +149.48% | -38.12 | 1 Comment |
| mpappa | 69.76 | 8/25/2014 |
|
3Y | $9.83 | +91.15% | +129.39% | -38.24 | 0 Comment | |
| line70day | < 20 | 7/30/2014 |
|
NS | $9.71 | +93.51% | +132.28% | -38.77 | 1 Comment | |
| Adepool | 91.94 | 10/6/2014 |
|
5Y | $9.76 | +92.52% | +132.64% | -40.12 | 0 Comment | |
| Asterix | < 20 | 12/1/2021 |
|
5Y | $36.57 | -48.62% | +0.12% | -48.73 | 0 Comment | |
| TerryHoodSr | 48.58 | 1/3/2014 |
|
5Y | $9.50 | +97.79% | +150.59% | -52.80 | 1 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
